Home › Uterine Cancer › California › San Francisco
Uterine Cancer clinical trials in San Francisco, CA
3 studies for Uterine Cancer are looking for participants at sites in and around San Francisco (within about 30 miles). Open a study to see who can join and how to contact the study team.
Recruiting for a study here? Feature it at the top of this page — $99 for 30 days →
DESTINY-Endometrial01: A Phase III Study of Trastuzumab Deruxtecan Plus Rilvegostomig or Pembrolizumab as First-Line Treatment of HER2-Expressing (IHC 3+/2+), Mismatch Repair Proficient (pMMR) Endometrial Cancer
RecruitingPhase 3
- Research Site, San Francisco
Zanzalintinib in Combination With Paclitaxel in Recurrent High Grade Uterine Cancer
RecruitingPhase 1
- University of California, San Francisco, San Francisco
A Study to Assess the Efficacy and Safety of FORE8394 in Participants With Cancer Harboring BRAF Alterations
RecruitingPhase 2
- UCSF Helen Diller Family Comprehensive Cancer Center, San Francisco
About Uterine Cancer
Uterine cancer is a cancer that forms in tissues of the uterus. It is more likely to happen after menopause. There are things you can do that may help lower your risk.
More about Uterine Cancer on MedlinePlus
Uterine Cancer trials in other cities
- Houston, TX8 studies
- New York City, NY7 studies
- Boston, MA7 studies
- Columbus, OH6 studies
- Austin, TX6 studies
- Philadelphia, PA6 studies
- Miami, FL5 studies
- Nashville, TN5 studies
- Orlando, FL4 studies
- Pittsburgh, PA4 studies
- West Palm Beach, FL4 studies
- Providence, RI4 studies
Other studies in San Francisco
- Prostate Cancer44 studies
- Breast Cancer40 studies
- Cancer (all types)38 studies
- Non-Small Cell Lung Cancer37 studies
- Heart Failure29 studies
- Metastatic Cancer25 studies
- Lung Cancer23 studies
- Melanoma21 studies
- Ovarian Cancer20 studies
- Cardiovascular Disease20 studies
- Pancreatic Cancer19 studies
- Glioblastoma19 studies
From ClinicalTrials.gov, data retrieved Nov 15, 2026. Each study sets its own eligibility; the study team decides who can join.